Prosight Management, LP Morphic Holding, Inc. Transaction History

Prosight Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $896,954 - $1.68 Million	-34,485 Reduced 80.29%	8,464 $318,000
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $1.04 Million - $1.3 Million	42,949 New	42,949 $1.15 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $2.64 Million - $3.79 Million	-72,898 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $125,396 - $190,456	2,898 Added 4.14%	72,898 $3.45 Million
Q3 2021 Nov 12, 2021	BUY	$53.61 - $67.5 $306,005 - $385,290	5,708 Added 8.88%	70,000 $3.97 Million
Q2 2021 Aug 13, 2021	BUY	$45.13 - $64.99 $2.67 Million - $3.84 Million	59,090 Added 1135.91%	64,292 $3.69 Million
Q1 2021 May 14, 2021	BUY	$29.77 - $84.85 $154,863 - $441,389	5,202 New	5,202 $329,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.